Yale Cancer Center Researchers have discovered a new role for the STimulator of INterferon Genes, or STING.
A test which uses artificial intelligence to measure proteins present in some patients with advanced bowel cancer could hold the key to more targeted treatment.
Patients with early-onset colorectal cancer, age 50 and younger, have a better survival rate than patients diagnosed with the disease later in life, a study by Yale Cancer Center researchers shows.
Patients with non-small cell lung cancer (whose cancer cells have low levels of—an abnormal number of chromosomes—tend to respond better to immune checkpoint inhibitor drugs than patients with higher levels, Dana-Farber Cancer Institute researchers found.
Early results from a chimeric antigen receptor T cell immunotherapy trial led by researchers at the UCLA Jonsson Comprehensive Cancer Center found using a bilateral attack instead of the conventional single-target approach helps minimizes treatment resistance, resulting in long-lasting remission for people with non-Hodgkin’s B-cell lymphoma that has come back or has not responded to treatment.
The Pancreatic Cancer Action Network has launched the Early Detection Initiative, the largest interventional study of its kind that will look at new onset diabetes and its correlation to pancreatic cancer.
Sets of genes associated with resistance to immunotherapy in patients with metastatic urothelial cancer of the bladder have been identified and validated by researchers at Mount Sinai.
Tumors consume glucose at high rates, but a team of researchers has discovered that cancer cells themselves are not the culprit, upending models of cancer metabolism that have been developed and refined over the last 100 years.
A team of pancreatic cancer researchers was formed to predict which treatments might work best for individual pancreatic cancer patients based on the molecular traits of tumors.
A study by researchers at the UCLA Jonsson Comprehensive Cancer Center found that using percutaneous image guided needle based thermal ablation is a safe and effective adjunctive therapy for the local control of metastatic gynecologic cancers throughout lungs, liver, soft tissues in the abdomen and pelvis and bones—and in patients with advanced localized cancers unresponsive to systemic therapy.
